Business UpdateMay 13, 2026, 04:07 PM
Insight Molecular Diagnostics Advances GraftAssureDx Commercialization
AI Summary
Insight Molecular Diagnostics reported significant progress towards commercializing its GraftAssureDx kidney transplant monitoring assay, including encouraging dialogue with the FDA for expected authorization later in 2026. The company also announced positive head-to-head data publications for its assay and the signing of the first clinical trial agreement for its GALACTIC registry study with a major U.S. transplant center. For Q1 2026, the company reported revenues of $32,000 and a net loss of $4.3 million, while maintaining a cash balance of $29.4 million after a recent $26.0 million offering.
Key Highlights
- FDA dialogue for GraftAssureDx authorization supports expected authorization later in 2026.
- First clinical trial agreement signed for GALACTIC study with a top 10 U.S. kidney transplant center.
- Positive head-to-head data on GraftAssure assay presented at EFI2026, showing comparable performance.
- Q1 2026 revenue was $32,000, primarily from laboratory services.
- Q1 2026 net loss was $4.3 million, or $0.12 per share.
- Cash, cash equivalents, and restricted cash totaled $29.4 million at March 31, 2026.
- Net cash used in operating activities was $7.6 million in Q1 2026.
- Completed a $26.0 million registered direct offering in February 2026, netting $24.6 million.